DAPA ACT HF-TIMI 68

DAPA ACT HF-TIMI 68 is an investigator-initiated, randomized, double-blind, placebo-controlled trial in patients with heart failure who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin on the clinical outcomes of cardiovascular death or worsening heart failure.

DAPA ACT HF-TIMI 68 Trial Schema 2022-03-08

DAPA ACT HF on ClinicalTrials.gov

CONTACT US about DAPA ACT HF

 

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close